22 May 2013
Keywords: tarceva, gets, negative, opinion, chmp, swiss, drug
Article | 07 August 2006
Swiss drug major Roche says that its anticancer agent Tarceva (eriotinib), developed in collaboration with US firm OSI
Pharmaceuticals, has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 August 2006
31 July 2006
© 2013 thepharmaletter.com